Skip to main content
An official website of the United States government

Talimogene Laherparepvec

Placeholder slot
 (tah-LIH-moh-jeen lah-HER-pah-REP-vek)

This page contains brief information about talimogene laherparepvec and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Imlygic
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Talimogene laherparepvec is approved to treat:

  • Melanoma in the skin and lymph nodes that cannot be removed by surgery. It is used as local treatment in patients whose disease has come back after being treated with surgery.

Talimogene laherparepvec is also being studied in the treatment of other types of cancer.

More About Talimogene Laherparepvec

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Talimogene Laherparepvec - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Oncolytic Virus Enables the Immune System to Attack Tumors

Cancer Treatment Vaccines

Clinical Trials Accepting Patients

Find Clinical Trials for Talimogene Laherparepvec - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email